The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS) Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302 The ALSTARS… Read More..

TAMPA, Fla., September 17, 2025--(BUSINESS WIRE)--AtlasClear Holdings, Inc. (NYSE American: ATCH) announces closing of $3,000,000 financing. AtlasClear Holdings, Inc. ("AtlasClear Holdings" or the "Company") reported today it raised $3,000,000 in gross proceeds through the issuance of promissory notes from strategic investors. The Company may raise up to an additional $2,000,000… Read More..

FORT LAUDERDALE, Fla., Sept. 17, 2025 (GLOBE NEWSWIRE) -- EdgeMode Inc. (OTC: EDGM), a leading provider of sustainable high-performance computing (“HPC”) infrastructure, today announced it has entered into a binding agreement with Blackberry AIF (BAIF) to acquire a portfolio of hyperscale data center development assets in Spain through a newly… Read More..